Actively Recruiting
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Led by Chinese PLA General Hospital · Updated on 2024-01-12
50
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
CONDITIONS
Official Title
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with dermatomyositis who are positive for anti-MDA5 antibodies
- Patients with anti-MDA5 antibody positive dermatomyositis and rapidly progressive interstitial lung disease (RPILD) who meet RPILD diagnostic criteria
- Patients who have undergone bronchoalveolar lavage
- Age 18 years or older
- Patients who have signed informed consent forms
You will not qualify if you...
- Patients with other connective tissue diseases
- Patients with interstitial lung disease or RPILD caused by infection, tumors, drugs, or biochemical factors
- Pregnant or lactating patients
- Patients currently participating in another clinical trial
- Patients who do not agree to participate in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
PLA
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Z
Zhimei Duan, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here